** Immunovant IMVT.O said on Wednesday its experimental treatment, batoclimab, for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer drug

** Analysts are looking into the development of IMVT-1402, the company's lead therapy candidate and its additional indications for autoimmune disorders

BEST-IN-CLASS AUTOIMMUNE THERAPY EMERGING

** Leerink Partners ("outperform", PT: $52) says the next-gen IMVT-1402 has a competitive advantage due to its convenient, low-volume dosage and is optimistic about the additional data due in 2026

** J.P.Morgan says IMVT-1402 will "outshine others" in indications such as Graves' disease and rheumatoid arthritis

** Oppenheimer Securities ("outperform", PT: $54) believes company's drug, IMVT-1402, has the potential to become the "preferred therapy for several autoimmune disorders"

** Truist Securities views Argenx's ARGX.BR Vyvgart's "first mover advantage coupled with physician comfort" will continue to make it the preferred agent ahead of IMVT-1402 and other competitors

(Reporting by Padmanabhan Ananthan)

((padmanabhan.ananthan@thomsonreuters.com))